- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-611/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Xellia Pharmaceuticals ApS, Alpharma LLC, formerly Zoetis Products LLC v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine — Rights of the defence — Reasonable time — Loss of documents due to the passage of time — General duty of care — Regulation (EC) No 1/2003 — Second subparagraph of Article 23(2) — Maximum amount of the fine — Taking into account the business year preceding that in which the European Commission’s decision was adopted — Last full year of normal economic activity)
ECLI:EU:UNKNOWN:62016CA0611
62016CA0611
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
31.5.2021
Official Journal of the European Union
C 206/5
(Case C-611/16 P) (<span class="oj-super oj-note-tag">1</span>)
(Appeal - Competition - Agreements, decisions and concerted practices - Pharmaceutical products - Market for antidepressants (citalopram) - Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines - Article 101 TFEU - Potential competition - Restriction by object - Characterisation - Calculation of the amount of the fine - Rights of the defence - Reasonable time - Loss of documents due to the passage of time - General duty of care - Regulation (EC) No 1/2003 - Second subparagraph of Article 23(2) - Maximum amount of the fine - Taking into account the business year preceding that in which the European Commission’s decision was adopted - Last full year of normal economic activity)
(2021/C 206/06)
Language of the case: English
Parties
Appellants: Xellia Pharmaceuticals ApS, Alpharma LLC, formerly Zoetis Products LLC (represented by: D.W. Hull, Solicitor)
Other party to the proceedings: European Commission (represented by: F. Castilla Contreras, T. Vecchi, B. Mongin and C. Vollrath, acting as Agents, B. Rayment and D. Bailey, Barristers, G. Peretz QC, and S. Kingston, Senior Counsel)
Intervener in support of the defendant: United Kingdom of Great Britain and Northern Ireland (represented by: initially D. Guðmundsdóttir, Z. Lavery and D. Robertson, acting as Agents, and J. Holmes QC, and subsequently D. Guðmundsdóttir, acting as Agent, and J. Holmes QC)
Operative part of the judgment
The Court:
1.Dismisses the appeal;
2.Orders Xellia Pharmaceuticals ApS and Alpharma LLC to bear their own costs and to pay the costs incurred by the European Commission;
3.Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.
*
Language of the case: English.
ECLI:EU:C:2025:140
OJ C 30, 30.1.2017.